Antigenics, Inc

Celgene, Corp.


7 Powder Horn Drive
Warren, NJ 07059

USA


Phone: (732) 271-1001
Fax: (732) 271-4184
Web Site: http://www.celgene.com/

 

  1. Company Profile

 

Celgene is a pharmaceutical company with a major focus on the discovery, development and commercialization of small molecules for cancer treatment.

 

  1. Products

 

Product Pipelines

 

Product

 

 

Indication

 

Clinical Status

Thalomid (Thalidomide)

 

Multiple myeloma

 

Market

Thalomid (Thalidomide)

 

Thyroid cancer

 

Phase III

 

Revimid

Chronic myelonic leukemia, myelodysplastic, and multiple myeloma

 

Phase II

 

Actimid

 

Prostate cancer

 

Phase II

 

1. Thalomid

 

Thalomid is new families of pharmaceuticals called Immunomodulatory Drugs. Its derivatives include Revimid and Actimid. These drugs mediate the production of cytokines and other growth factors that are responsible for growth and survival of tumor cells. They lower levels of the proangiogenenic cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). They also prevent the growth of tumor tissue by inhibiting the attachment of stromal cells to tumor cells, a key requirement for optimal growth and survival of tumor cells. The ability to promote the cell cycle arrest and predispose cancer cells to apoptosis (programmed cell death) is another activity associated with these agents. They also direct the immune system to target cancer cells for destruction by natural killer (NK) cells and cytotoxic T lymphocytes.

 

 

2. Revimid

 

Revimid (CC-5013) is a potent thalidomide.

 

3. Actimid

Actimid is an orally available compound that is chemically linked, but functionally distinct from thalidomide.